AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Talphera Appoints CorMedix CEO Joe Todisco to Board of Directors.
ByAinvest
Tuesday, Oct 21, 2025 8:33 am ET1min read
• Talphera appoints Joe Todisco as Board of Directors member • Todisco is CEO of CorMedix, which invested in Talphera in September 2025 • CorMedix has right to nominate representative to Talphera Board • CorMedix has 60-day exclusive negotiation period to acquire Talphera
Talphera, Inc. (NASDAQ: TLPH) has appointed Joe Todisco as a Class III director and member of the compensation committee, effective September 12, 2025 [1]. Todisco, who currently serves as the CEO of CorMedix Inc. (NASDAQ: CRMD), brings extensive experience in the pharmaceutical industry to Talphera's board. His appointment follows a strategic investment by CorMedix in Talphera in September 2025, which granted CorMedix the right to nominate a representative to Talphera's board [2].Todisco, 49, has held senior roles at various pharmaceutical companies, including Amneal Pharmaceuticals and Ranbaxy. He co-founded Gemini Laboratories and holds an MBA in Finance from Fordham Graduate School of Business and a BA in Economics from Georgetown University [1]. His appointment includes a restricted stock unit grant and options to purchase shares of Talphera common stock, vesting over three years [1].
CorMedix's strategic investment provides Talphera with financial support, while also giving CorMedix the right to designate a Talphera board member. Additionally, CorMedix has a 60-day exclusive negotiation period to acquire Talphera following the announcement of key clinical study results for Talphera's Niyad product candidate [2].
Talphera's Niyad, a lyophilized formulation of nafamostat, is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. The company has reached 25% enrollment in its NEPHRO CRRT pivotal clinical trial, with 17 out of 70 patients enrolled [2]. Talphera is navigating market challenges, including supply chain issues impacting the anticoagulation sector, and has reported strategic reductions in operating expenses [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet